BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35963908)

  • 1. Loss of FGFR4 promotes the malignant phenotype of PDAC.
    D'Agosto S; Pezzini F; Veghini L; Delfino P; Fiorini C; Temgue Tane GD; Del Curatolo A; Vicentini C; Ferrari G; Pasini D; Andreani S; Lupo F; Fiorini E; Lorenzon G; Lawlor RT; Rusev B; Malinova A; Luchini C; Milella M; Sereni E; Pea A; Bassi C; Bailey P; Scarpa A; Bria E; Corbo V
    Oncogene; 2022 Sep; 41(38):4371-4384. PubMed ID: 35963908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
    Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z
    Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.
    Camolotto SA; Belova VK; Torre-Healy L; Vahrenkamp JM; Berrett KC; Conway H; Shea J; Stubben C; Moffitt R; Gertz J; Snyder EL
    Gut; 2021 May; 70(5):900-914. PubMed ID: 32826305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
    Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
    Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of the classical phenotype upon integration of pancreatic cancer cells into the duodenal epithelium.
    Bozóky B; Fernández Moro C; Strell C; Geyer N; Heuchel RL; Löhr JM; Ernberg I; Szekely L; Gerling M; Bozóky B
    Neoplasia; 2021 Dec; 23(12):1300-1306. PubMed ID: 34798385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis.
    Yun Z; Meng F; Li S; Zhang P
    Aging (Albany NY); 2021 Feb; 13(4):6041-6054. PubMed ID: 33581689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
    Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
    Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression.
    Chen G; Tian X; Liu Z; Zhou S; Schmidt B; Henne-Bruns D; Bachem M; Kornmann M
    Br J Cancer; 2010 Jan; 102(1):188-95. PubMed ID: 19920824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer.
    Ohara Y; Tang W; Liu H; Yang S; Dorsey TH; Cawley H; Moreno P; Chari R; Guest MR; Azizian A; Gaedcke J; Ghadimi M; Hanna N; Ambs S; Hussain SP
    Cell Rep; 2023 Dec; 42(12):113434. PubMed ID: 37980563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer.
    Sasaki N; Gomi F; Yoshimura H; Yamamoto M; Matsuda Y; Michishita M; Hatakeyama H; Kawano Y; Toyoda M; Korc M; Ishiwata T
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Zhu L; Wang X
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
    Han T; Zhuo M; Yuan C; Xiao X; Cui J; Qin G; Wang L; Jiao F
    Cancer Biol Med; 2020 Nov; 17(4):953-969. PubMed ID: 33299646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.
    Feldmann K; Maurer C; Peschke K; Teller S; Schuck K; Steiger K; Engleitner T; Öllinger R; Nomura A; Wirges N; Papargyriou A; Jahan Sarker RS; Ranjan RA; Dantes Z; Weichert W; Rustgi AK; Schmid RM; Rad R; Schneider G; Saur D; Reichert M
    Gastroenterology; 2021 Jan; 160(1):346-361.e24. PubMed ID: 33007300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Ductal Epithelial Cells.
    Otto L; Rahn S; Daunke T; Walter F; Winter E; Möller JL; Rose-John S; Wesch D; Schäfer H; Sebens S
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.
    Gauglhofer C; Paur J; Schrottmaier WC; Wingelhofer B; Huber D; Naegelen I; Pirker C; Mohr T; Heinzle C; Holzmann K; Marian B; Schulte-Hermann R; Berger W; Krupitza G; Grusch M; Grasl-Kraupp B
    Carcinogenesis; 2014 Oct; 35(10):2331-8. PubMed ID: 25031272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.
    Ruta V; Naro C; Pieraccioli M; Leccese A; Archibugi L; Cesari E; Panzeri V; Allgöwer C; Arcidiacono PG; Falconi M; Carbone C; Tortora G; Borrelli F; Attili F; Spada C; Quero G; Alfieri S; Doglioni C; Kleger A; Capurso G; Sette C
    Cell Rep Med; 2024 Feb; 5(2):101411. PubMed ID: 38325381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
    Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
    J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.
    Bai Z; Sun J; Wang X; Wang H; Pei H; Zhang Z
    Oncol Rep; 2015 Aug; 34(2):595-602. PubMed ID: 26062664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
    Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
    J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.